Manuka Health New Zealand Ltd
The active compound of Manuka Honey was identified in 2006. Since 2008, Manuka Health has used this scientific standard to measure and label its MGO® Manuka Honey.
For example, MGO® 100+ Manuka Honey has been tested and certified to contain at least 100mg/kg of methylglyoxal.
With strengths ranging from MGO® 30 – 550 Manuka Honey, consumers can choose the product to suit their needs.
Manuka Health's BIO New Zealand Propolis™ is the world's first bee propolis with certified levels of bioactive compounds including Caffeic Acid Phenethyl Ester (CAPE) and major bioflavonoids.
BIO New Zealand Propolis™ has up to six times the amount of CAPE than propolis from other origins. Scientists believe that this is due New Zealand's flora developing in isolation for over 80 million years.
Manuka Health has developed a range of woundcare products using medical grade Manuka honey. The retail range consists of wound gel, wound dressings, and breast pads for nursing mothers.
The medical range, for professional use, includes a broader range of sizes and packaging options for hospital and clinical use.
Recent studies show Manuka honey to be pivotal in the fight against MRSA.
The first two CycloPower™ products have hit the shelves in New Zealand. CycloPower™ with Manuka Honey – capsules for digestive support and chewable tablets for mouth and throat.
Studies have shown that manuka honey is effective against a range of bacteria. However, CycloPower™ with Manuka Honey provides significantly greater antibacterial activity than manuka honey with the same level of methylglyoxal.